betulinic acid

Overview

Betulinic acid (BA) is a naturally occurring pentacyclic triterpenoid compound predominantly isolated from the bark of Betula alba (white birch) and other plant species. It belongs to the lupane-type triterpenoid family and is characterized by its hydrophobic structure, which underlies both its biological potency and its pharmacokinetic challenges. Betulinic acid has attracted substantial scientific interest due to its broad spectrum of biological activities, including anti-inflammatory, antioxidant, and anticancer properties. Its anticancer mechanisms are particularly well-characterized and involve the upregulation of proapoptotic proteins, modulation of NF-κB signaling, and inhibition of topoisomerase I, positioning it as a structurally privileged scaffold for drug discovery and natural product chemistry.

Beyond its direct cytotoxic effects, betulinic acid engages multiple intracellular signaling axes relevant to metabolic stress, oxidative damage, and cellular survival. Its ability to modulate pathways such as AMPK/mTOR and interact with kinase targets like BRAF makes it a versatile candidate for research spanning oncology, metabolic bone disease, and inflammation. The compound is also found as a constituent in various medicinal plant species, and efforts to improve its bioavailability and target specificity through glycosylation and structural modification are active areas of investigation.

Focus of Latest Publications

Recent literature has explored betulinic acid across a diverse set of disease contexts and mechanistic questions, reflecting its multifunctional pharmacological profile.

Osteoporosis and Osteoblast Protection A 2026 study published in the International Journal of Molecular Medicine investigated BA's role in alleviating inflammatory injury in osteoblasts, a key concern in osteoporosis and Age-related osteogenic failure. The study demonstrated that BA exerts its protective effects by augmenting autophagy through the AMPK/mTOR signaling pathway. Specifically, BA appeared to activate AMP-activated protein kinase (AMPK) while suppressing mechanistic target of rapamycin kinase (mTOR), thereby promoting autophagic flux in osteoblasts subjected to inflammatory stress. This mechanistic axis is of broad therapeutic relevance, as dysregulation of autophagy pathways has been implicated in the progressive bone loss characteristic of osteoporosis. The finding aligns BA with a growing class of natural compounds capable of targeting AMPK/mTOR to restore cellular homeostasis under inflammatory conditions.

breast cancer: Apoptosis, miR-21, and Redox Modulation A study in Scientific Reports (2026) examined BA's activity in breast cancer cells, combining in vitro experiments with in silico modeling. The research focused on triple-negative breast adenocarcinoma cells and found that BA is associated with modulation of miR-21 — a well-established oncogenic microRNA — alongside induction of apoptosis and redox changes. The compound's anticancer action was contextualized within its known mechanisms: upregulation of proapoptotic proteins, NF-κB modulation, and topoisomerase I inhibition. The study also involved in silico analysis, further characterizing the molecular interactions underlying BA's cytotoxic selectivity. These findings add to a body of evidence suggesting BA can engage multiple nodes of cancer cell survival, potentially overlapping with pathways involving PTEN and SIRT1/HIF-1α, which are frequently dysregulated in aggressive breast cancer subtypes.

Anti-Inflammatory Activity in Plant Metabolite Profiling A phytochemical profiling study published in Scientific Reports (2026) analyzed the fruit of Ficus natalensis Hochst. using UPLC-MS/MS and identified betulinic acid as one of several major bioactive constituents alongside gallic acid, ellagic acid, and quercetin derivatives. The authors proposed that these compounds, including BA, may collectively underlie the observed anti-inflammatory activity of the plant extract. This finding situates betulinic acid within the broader context of multi-compound botanical matrices, reinforcing its relevance as a bioactive marker in ethnopharmacological and food science research. The concurrent presence of compounds such as gallic acid — itself a known antioxidant and anti-inflammatory agent — suggests potential synergistic interactions within complex plant extracts.

Biosynthesis and Glycosylation for Improved Bioavailability A 2026 paper in the Journal of Agricultural and Food Chemistry reported on the engineering of highly regioselective carboxyl glycosyltransferases for triterpenoid glycoside biosynthesis. Betulinic acid was successfully glycosylated in vitro to produce 28-O-glc-betulinic acid, achieving a 95% theoretical UDP recycling efficiency using a designed enzyme cascade that incorporated sucrose synthase and uridine diphosphate glucose as a co-substrate regeneration system. This biotransformation was performed using engineered yeast systems and represents a significant advance in the sustainable production of betulinic acid glycosides, which typically exhibit improved water solubility relative to the parent aglycone. The efficient UDP recycling strategy reduces the cost burden of enzymatic glycosylation at scale, making this approach industrially relevant.

In Silico Evaluation Against BRAF Kinases A computational study in the Journal of Molecular Modeling (2026) assessed betulinic acid and other triterpenes as potential inhibitors of wild-type BRAF and the oncogenic BRAF^V600E^ mutant kinase — a critical driver in melanoma and several other cancers. Molecular docking analysis revealed that BA exhibits a binding free energy (ΔG) of −57.46 kcal/mol in complex with wild-type BRAF^WT^, a value comparable to established BRAF inhibitors such as vemurafenib-OMe and dabrafenib reported in prior work. These results position BA as a structurally interesting scaffold for further optimization as a BRAF-targeted agent, although in vitro and in vivo validation will be required to substantiate the computational predictions. The BRAF gene and its V600E variant remain among the most clinically significant oncogenic targets, and the inclusion of betulinic acid in this analysis suggests potential for rational drug design around its triterpenoid core.

Key Publications

May Betulinic acid is associated with miR-21 modulation, apoptosis and redox changes in breast cancer cells: an in vitro and in silico study. (Scientific reports, 2026, PMID 42143107): "Betulinic acid is defined as a hydrophobic pentacyclic triterpenoid primarily found in the bark of Betula alba, known for its anticancer activity through mechanisms such as upregulating proapoptotic proteins, modulating NF-kB, and inhibiting topoisomerase I."
May Betulinic acid alleviates the inflammatory injury of osteoblasts in osteoporosis by augmenting autophagy via the AMPK-mTOR signaling pathway. (International journal of molecular medicine, 2026, PMID 42138188): "Betulinic acid (BA), a natural pentacyclic triterpenoid compound, exhibits anti-inflammatory and antioxidant biological effects."
May Profiling metabolites of Ficus natalensis hochst. fruit by UPLC-MS/MS and evaluation of anti-inflammatory activity. (Scientific reports, 2026, PMID 42129402): "Major bioactive constituents, including ellagic acid, gallic acid, betulinic acid, and quercetin derivatives, were identified and may underline the observed anti-inflammatory effect."
May Mining of Highly Regioselective Carboxyl Glycosyltransferases and Their Application in Biosynthesizing Triterpenoid Glycosides. (Journal of agricultural and food chemistry, 2026, PMID 42044306): "With this enzyme cascade, betulinic acid was in vitro glycosylated to produce 28-O-glc-betulinic acid with a 95% theoretical UDP recycling efficiency."
Apr In silico evaluation of selected triterpenes as potential inhibitors of BRAF and BRAFV600E kinases for cancer treatment. (Journal of molecular modeling, 2026, PMID 42043592): "The ΔG of betulinic acid (-57.46 kcal/mol) in complex with BRAFWT is comparable to the BRAF inhibitors vemurafenib-OMe and dabrafenib reported in previous work."